Chemogenomics knowledge-based strategies in drug discovery

被引:31
作者
Jacoby, E [1 ]
Schuffenhauer, A [1 ]
Floersheim, P [1 ]
机构
[1] Novartis Pharma AG, Novartis Nervous Syst Res, CH-4002 Basel, Switzerland
关键词
D O I
10.1358/dnp.2003.16.2.829326
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the postgenomic age of drug discovery, targets can no longer be viewed as singular objects having no relationship to one another. All targets are now visible and the systematic exploration of selected target families appears to be a promising way to speed up and further industrialize target-based drug discovery. Chemogenomics refers to such systematic exploration of target families and aims to identify all possible ligands of all target families. Because biology works by applying prior knowledge to an unknown entity, chemogenomics approaches are expected to be especially effective within the previously well-explored target families, for which, in addition to the protein sequence and structure information, considerable knowledge of pharmacologically active structural classes and structure-activity relationships exists. For the new target families, chemical knowledge will have to be generated and beyond biological target validation, the emphasis is on chemistry to provide the molecules with which their novel biology and pharmacology can be studied. Using examples from the previously most successfully explored target families, the GPCR family in particular, we summarize herein our current chemogenomics knowledge-based strategies for drug discovery, which are founded on the high integration of chem and bioinformatics, thereby providing a molecular informatics frame for the exploration of the new target families. (C) 2003 Prous Science. All rights reserved.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 48 条
[21]  
Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO
[22]  
2-5
[23]   Orphan nuclear receptors: Shifting endocrinology into reverse [J].
Kliewer, SA ;
Lehmann, JM ;
Willson, TM .
SCIENCE, 1999, 284 (5415) :757-760
[24]   LGICdb:: the ligand-gated ion channel database [J].
Le Novère, N ;
Changeux, JP .
NUCLEIC ACIDS RESEARCH, 2001, 29 (01) :294-295
[25]  
Martin G. R, 2000, IUPHAR COMPENDIUM RE, P233
[26]  
*MDL INF SYST INC, MDL DRUG DAT REP
[27]   Protein sequence analysis in silico:: application of structure-based bioinformatics to genomic initiatives [J].
Michalovich, D ;
Overington, J ;
Fagan, R .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (05) :574-580
[28]   Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists - Binding to a common chemokine receptor motif within the helical bundle [J].
Mirzadegan, T ;
Diehl, F ;
Ebi, B ;
Bhakta, S ;
Polsky, I ;
McCarley, D ;
Mulkins, M ;
Weatherhead, GS ;
Lapierre, JM ;
Dankwardt, J ;
Morgans, D ;
Wilhelm, R ;
Jarnagin, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25562-25571
[29]   Transforming the genome to drug discovery [J].
Murcko, M ;
Caron, P .
DRUG DISCOVERY TODAY, 2002, 7 (11) :583-584
[30]  
NEUMANN P, 1997, Patent No. 9703054